<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Strickland, Cindy H.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nano-based drugs and medical devices : FDA's track record  </style></title><secondary-title><style face="normal" font="default" size="100%">nanotechnology Law and Business </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">06/2007</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">4</style></volume><language><style face="normal" font="default" size="100%">English </style></language><abstract><style face="normal" font="default" size="100%">This article looks at several medical products and drugs containing engineered nanomaterials that have been approved by the U.S. Food and Drug Administration (FDA), discusses the nature and extent of their FDA reviews, and makes some observations about the trends that appear to be emerging.  </style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>